REGENXBIO Inc. (RGNX)

Market Cap	440.40M
Revenue (ttm)	156.72M
Net Income (ttm)	-157.69M
Shares Out	50.39M
EPS (ttm)	-3.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	423,878
Open	8.63
Previous Close	8.62
Day's Range	8.46 - 8.93
52-Week Range	5.04 - 15.36
Beta	1.09
Analysts	Strong Buy
Price Target	31.75 (+263.27%)
Earnings Date	Jul 31, 2025

About RGNX

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 17, 2015
• Employees: 353
• Stock Exchange: NASDAQ
• Ticker Symbol: RGNX
• Website: https://www.regenxbio.com

Financial Performance

In 2024, REGENXBIO's revenue was $83.33 million, a decrease of -7.66% compared to the previous year's $90.24 million. Losses were -$227.10 million, -13.81% less than in 2023.

Analyst Summary

According to 8 analysts, the average rating for RGNX stock is "Strong Buy." The 12-month stock price target is $31.75, which is an increase of 263.27% from the latest price.

Price Target

$31.75

(263.27% upside)

Analyst Consensus: Strong Buy